{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T00:32:38Z","timestamp":1712449958622},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,4,1]]},"DOI":"10.2169\/internalmedicine.2270-23","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T22:12:24Z","timestamp":1691532744000},"page":"985-988","source":"Crossref","is-referenced-by-count":0,"title":["PD-L1-negative Non-small-cell Lung Cancer Treated with Nivolumab Plus Ipilimumab during Maintenance Hemodialysis Results in Rapid Initial Progression Followed by a Long-lasting Response"],"prefix":"10.2169","volume":"63","author":[{"given":"Shohei","family":"Yano","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Uematsu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Kunimune","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Harima","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Nishizaka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Osaka Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424, 2018.","DOI":"10.3322\/caac.21492"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Voruganti T, Soulos PR, Mamtani R, Presley CJ, Gross CP. Association between age and survival trends in advanced non-small cell lung cancer after adoption of immunotherapy. JAMA Oncol 9: 334-341, 2023.","DOI":"10.1001\/jamaoncol.2022.6901"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 385: 1975-1982, 2015.","DOI":"10.1016\/S0140-6736(14)61601-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Janus N, Launay-Vacher V, Thyss A, et al. Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol 24: 501-507, 2013.","DOI":"10.1093\/annonc\/mds344"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 381: 2020-2031, 2019.","DOI":"10.1056\/NEJMoa1910231"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kobayashi Y, Arai H, Honda M. Nivolumab and ipilimumab immunotherapy for hemodialysis patients with advanced renal cell carcinoma. Curr Oncol 27: 225-228, 2020.","DOI":"10.3747\/co.27.6439"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Iwaki T, Niimi A, Kano M, et al. Safe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma. IJU Case Rep 4: 32-35, 2021.","DOI":"10.1002\/iju5.12231"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Shaw LK, Wiele AJ, Sircar K, Wood CG, Msaouel P. Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis. Cancer Treat Res Commun 27: 100349, 2021.","DOI":"10.1016\/j.ctarc.2021.100349"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Masuda H, Mikami K, Otsuka K, et al. Successful response to nivolumab plus ipilimumab therapy in a hemodialysis patient with metastatic renal cell carcinoma. Cancer Diagn Progn 1: 207-211, 2021.","DOI":"10.21873\/cdp.10028"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kobari Y, Yoshida K, Iizuka J, et al. Three cases of nivolumab plus ipilimumab therapy in haemodialysis patients with metastatic renal cell carcinoma. In Vivo 35: 3585-3589, 2021.","DOI":"10.21873\/invivo.12663"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Takahashi M, Takishita M, Yamazato Y, et al. Two cases of nivolumab plus ipilimumab therapy for dialysis patients with advanced bone metastasis from renal cell carcinoma. CEN Case Rep 12: 237-241, 2022.","DOI":"10.1007\/s13730-022-00753-8"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Pasquiers B, Benamara S, Felices M, Nguyen L, Decl\u00e8ves X. Review of the existing translational pharmacokinetics modeling approaches specific to monoclonal antibodies (mAbs) to support the first-in-human (FIH) dose selection. Int J Mol Sci 23: 12754, 2022.","DOI":"10.3390\/ijms232112754"},{"key":"13","unstructured":"13. Zhao D, Long X, Fan H, Wang J. Effects of hepatic or renal impairment on the pharmacokinetics of immune checkpoint inhibitors. Am J Cancer Res 12: 4892-4903, 2022."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Mroue A, Moujaess E, Kourie HR, Azar H, Finianos S, Chelala D. Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: a systematic review of the literature. Crit Rev Oncol Hematol 157: 103169, 2021.","DOI":"10.1016\/j.critrevonc.2020.103169"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2: 1346-1353, 2016.","DOI":"10.1001\/jamaoncol.2016.1051"},{"key":"16","unstructured":"16. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36: 1714-1768, 2018."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Dromain C, Beigelman C, Pozzessere C, Duran R, Digklia A. Imaging of tumour response to immunotherapy. Eur Radiol Exp 4: 2, 2020.","DOI":"10.1186\/s41747-019-0134-1"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Tanizaki J, Hayashi H, Kimura M, et al. Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression. Lung Cancer 102: 44-48, 2016.","DOI":"10.1016\/j.lungcan.2016.10.014"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Watanabe Y, Ogawa M, Tamura Y, et al. A case of pseudoprogression in hepatocellular carcinoma treated with atezolizumab plus bevacizumab. J Investig Med High Impact Case Rep 9: 23247096211058489, 2021.","DOI":"10.1177\/23247096211058489"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/7\/63_2270-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T03:37:49Z","timestamp":1712374669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/7\/63_2270-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2270-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,1]]},"article-number":"2270-23"}}